Soliman A T, elZalabany M M, Ragab M, Abdel Fattah M, Hassab H, Rogol A D, Ansari B M
Department of Pediatrics, University of Alexandria, Egypt.
J Trop Pediatr. 2000 Apr;46(2):79-85. doi: 10.1093/tropej/46.2.79.
To elucidate whether the cause of sexual maturation arrest in thalassaemia is of gonadal or pituitary etiology, 10 males with thalassaemia and delayed puberty and 10 with constitutional delay of growth and pubertal maturation (CSS) were extensively studied. Their spontaneous nocturnal gonadotropin secretion and gonadotropin response to intravenous 100 micrograms gonadotropin-releasing hormone (GnRH) were evaluated. Circulating testosterone concentration and clinical response were evaluated after 3 days, 4 weeks and 6 months of intramuscular administration of human chorionic gonadotropin (HCG) (2500 U/m2/dose). Thalassaemic boys had significantly lower circulating concentrations of testosterone compared to those with constitutional delay of growth and sexual maturation (CSS) at the same pubertal stage. Short- and long-term testosterone response to administrations of HCG was markedly decreased in thalassaemic boys. After 6 months of HCG administration 50 per cent (5/10) of the boys did not show significant testicular enlargement or genital changes. Despite the low circulating concentrations of testosterone, none of the patients had high basal or exaggerated gonadotropin response to gonadotropin releasing hormone (GnRH) stimulation. Luteinizing hormone (LH) peak responses to GnRH were significantly lower as compared to controls. Follicle-stimulating hormone (FSH) peak responses to GnRH did not differ among the two study groups. The mean nocturnal LH and FSH secretion was significantly decreased in all thalassaemic boys as compared to boys with CSS at the same pubertal stage (testicular volume). These data proved that hypogonadotropic hypogonadism is the main cause of delayed/failed puberty in adolescents with thalassaemia major. MRI studies revealed complete empty sella (n = 5), marked diminution of the pituitary size (n = 5), thinning of the pituitary stalk (n = 3) with its posterior displacement (n = 2), and evidence of iron deposition in the pituitary gland and midbrain (n = 8) in thalassaemic patients, denoting a high incidence of structural abnormalities (atrophy) of the pituitary gland. Moreover, in many of the thalassaemic boys, the defective testosterone response to long-term (6 months) HCG therapy denoted significant testicular atrophy and/or failure secondary to siderosis. It appears that testosterone replacement might be superior to HCG therapy in these patients. This therapy should be introduced at the proper time in these hypogonadal patients to induce their sexual development and to support their linear growth spurt and bone mineral accretion.
为了阐明地中海贫血患者性成熟停滞的原因是性腺还是垂体源性的,对10例患有地中海贫血且青春期延迟的男性以及10例体质性生长和青春期成熟延迟(CSS)的男性进行了广泛研究。评估了他们夜间促性腺激素的自发分泌以及促性腺激素对静脉注射100微克促性腺激素释放激素(GnRH)的反应。在肌肉注射人绒毛膜促性腺激素(HCG)(2500 U/m²/剂量)3天、4周和6个月后,评估循环睾酮浓度和临床反应。与处于相同青春期阶段的体质性生长和性成熟延迟(CSS)的男孩相比,地中海贫血男孩的循环睾酮浓度显著降低。地中海贫血男孩对HCG给药的短期和长期睾酮反应明显降低。在注射HCG 6个月后,50%(5/10)的男孩未出现明显的睾丸增大或生殖器变化。尽管睾酮的循环浓度较低,但没有患者对促性腺激素释放激素(GnRH)刺激有高基础或过度的促性腺激素反应。与对照组相比,黄体生成素(LH)对GnRH的峰值反应显著降低。两个研究组之间促卵泡激素(FSH)对GnRH的峰值反应没有差异。与处于相同青春期阶段(睾丸体积)的CSS男孩相比,所有地中海贫血男孩夜间LH和FSH的平均分泌显著降低。这些数据证明,低促性腺激素性性腺功能减退是重型地中海贫血青少年青春期延迟/失败的主要原因。MRI研究显示,地中海贫血患者中存在完全空蝶鞍(n = 5)、垂体大小明显减小(n = 5)、垂体柄变细(n = 3)及其向后移位(n = 2),以及垂体和中脑有铁沉积的证据(n = 8),这表明垂体结构异常(萎缩)的发生率很高。此外,在许多地中海贫血男孩中,对长期(6个月)HCG治疗的睾酮反应缺陷表明存在明显的睾丸萎缩和/或继发于铁沉着症的功能衰竭。在这些患者中,睾酮替代疗法似乎优于HCG疗法。应在这些性腺功能减退患者的适当时间引入这种疗法,以诱导他们的性发育,并支持他们的线性生长突增和骨矿物质增加。